BRIEF-ImmunoCellular Therapeutics down 57.4 percent premarket after phase II glioblastoma treatment results
December 12, 2013 at 07:57 AM EST
NEW YORK, Dec 12 (Reuters) - ImmunoCellular Therapeutics Ltd : * Down 57.4 percent to $1.16 in premarket after phase II glioblastoma treatment results